Sanofi (NASDAQ:SNY) Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans boosted its position in Sanofi (NASDAQ:SNY) by 28,890.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,429,219 shares of the company’s stock after purchasing an additional 1,424,289 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Sanofi were worth $82,366,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Chesapeake Capital Corp IL purchased a new position in shares of Sanofi during the 3rd quarter worth $543,000. Atlanta Consulting Group Advisors LLC purchased a new position in Sanofi during the third quarter worth about $1,111,000. Natixis Advisors LLC boosted its stake in Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after buying an additional 114,133 shares during the last quarter. Simplify Asset Management Inc. purchased a new stake in Sanofi in the 3rd quarter valued at about $11,765,000. Finally, Arjuna Capital acquired a new position in shares of Sanofi during the 3rd quarter valued at about $2,245,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Up 0.3 %

Shares of SNY stock opened at $47.97 on Monday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The firm’s 50 day moving average price is $54.65 and its two-hundred day moving average price is $52.23. The stock has a market cap of $121.74 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the previous year, the business posted $2.55 EPS. The business’s quarterly revenue was up 12.3% on a year-over-year basis. On average, analysts anticipate that Sanofi will post 4.29 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on SNY shares. Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.